The Editor-in-Chief Guangwen Cao and 4 Editorial Board Members of Hepatoma Research Are Featured in Elsevier 2021 "Highly Cited Chinese Researchers"
On April 14, 2022, Elsevier released the list of "Highly Cited Chinese Researchers" in 2021. The list takes Scopus, the global authoritative citation and index database, as the statistical source of Chinese scholars' scientific research achievements, and adopts the selection method designed by Soft Science (Shanghai Soft Science Education Information Consulting Co., Ltd.), and finally listed 4701 Chinese scholars with the most global influence in various disciplines from 523 universities, enterprises, and scientific research institutions. The list aims to identify researchers in China who have significant influence in their field by publishing highly cited papers during the last decade.
The Editor-in-Chief Prof. Guang-Wen Cao, Associate Editors Jia Fan, Jin-Lin Hou, Kai-Chun Wu, and the Editorial Board member Xin-Yuan Guan were named to the list of Elsevier 2021 "Highly Cited Chinese Researchers".
Dr. Guang-Wen Cao is the chairman, professor, and PhD supervisor at Department of Epidemiology, Second Military Medical University (Shanghai, China). He is the principal scientist of the national key basic research program (973 program), the National Outstanding Youth Scholar, the professor for a special post of “Chang-Jiang scholar award scheme”, and the leading scientist in Oncology, especially in liver cancer. Currently, Dr. Cao also chairs the water-related disaster branch of Chinese medical association of disaster rescue, serves as the vice-president of Shanghai preventive medicine society, and the Editor-in-Chief of Hepatoma Research. Dr. Cao graduated from the Second Military Medical University and got his PhD degree, master degree, and bachelor degree of clinical medicine, respectively. After graduating, Dr. Cao received his 3.5-year post-doctoral training at Baylor College of Medicine and UT MD Anderson cancer center in Texas, USA. The major research interests are to elucidate the mechanisms by which cancers develop and metastasize, identify novel diagnostic, predictive, and prognostic biomarkers, as well as therapeutic targets for some malignancies. Dr. Cao is in charge of the national research projects, including the key project, integrated project, key international collaborative project, and COVID-19 specific project from the National Natural Scientific Foundation (NSFC) of China. As the first or corresponding author, Dr. Cao published 158 papers in professional English journals. Of those, 17 papers were published in journals with impact factors of greater than 10. For the first time, Dr. Cao originated a theory of Cancer Evo-Dev, based on his research on hepatitis B virus (HBV)-induced hepatocarcinogenesis and malignancies of other histotypes like colorectal carcinoma, renal cell carcinoma, and gastric cancer. Served as the editor-in-chief, Dr. Cao published 10 books including Cancer Evo-Dev. As the first winner, Dr. Cao received the National Natural Science Award in 2019, the Natural Science Award of the first degree Department of Education in 2018, the Science and Technology Progress Award of the first degree in Shanghai in 2018, the Science and Technology Progress Award of the first degree, PLA in 1999, the Science and Technology Award of the first degree, Shanghai Medical Association in 2010. Moreover, Dr. Cao was also awarded the National Science and Technology Progress Award of the second degree in 2004 and 2011, as well as the National Science and Technology Team Award in 2012. Dr. Cao got a total of 36 Science and Technology Awards, and 15 approved patents.
Dr. Jia Fan is an Academician of Chinese Academy of Sciences, president of Zhongshan Hospital, vice-director of Liver Cancer Institute, Fudan University. He is also a professor of liver surgery and director of Department of Oncology and Organ Transplantation Center, Zhongshan Hospital, Fudan University. Professor Jia Fan is dedicated to clinical diagnosis, treatment, and basic research of liver cancer. His major contributions to liver cancer study are as follows: He has performed more than 9000 cases of liver resection for liver cancer, and successfully performed liver transplantation for more than 2200 cases. He extended the Milan criteria to “Shanghai-Fudan criteria” in HCC patients. In basic research, his group identified a plasma microRNA panel, which has translated to clinical usage successfully for the early diagnosis of HCC. In the study of liver cancer metastasis, his group discovered a variety of new mechanisms, including the identification of novel predictors, therapeutic targets, as well as the role of the tumor microenvironment in HCC metastasis. So far, he has published more than 140 papers as the first or the corresponding author in SCI journals, such as Nature, Lancet Oncology, J Clinical Oncology, Gastroenterology and Hepatology. He was awarded prizes in the State Science and Technology Awards for his outstanding contribution to comprehensive management of portal vein tumor thrombosis of HCC and prevention and treatment strategies of tumor recurrence following liver transplantation. He also was awarded the first prize in natural science by Ministry of Education for his basic research in HCC tumor microenvironment.
Dr. Jin-Lin Hou, Professor, is the Director and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, China. Previously, Professor Hou served as President of the Chinese Medical Association of Infectious Diseases, as well as President of APASL 2017. He has been invited to deliver talks at both national and international liver conferences owing to his expertise in viral hepatitis. His current research interests include the clinical management of viral hepatitis and the molecular virology and immunology of hepatitis B virus (HBV) and severe acute respiratory syndrome (SARS) infection. Professor Hou has published more than 400 articles peer-reviewed journals, including Hepatology, Journal of Hepatology, Gut, Gastroenterology, NEJM, Lancet Infectious Diseases and Science, et al.
Dr. Kai-Chun Wu is a professor and the Deputy Chair of Xijing Hospital of Digestive Diseases, the Fourth Military Medical University. He received his MD & PhD degrees from the Fourth Military Medical University and post-doc training at Nottingham University (UK). He got his research experience at Oxford University(UK), and Northwestern University(USA). He serves as Vice-President of Chinese Society of Gastroenterology(CSG) and Council Member of the World Gastroenterology Organisation(WGO) and Asia Pacific Association of Gastroenterology(APAGE). Member of the Standing Committee and Secretary General of the Gastroenterology Branch of the Chinese Medical Association, Executive Director and Chairman of the Award Committee of the Asia-Pacific Gastroenterology Association, etc. Professor Wu has published more than 300 papers in peer-reviewed journals like Gastroenterology, Hepatology, J Hepatol, Oncogene, J Immunol, FASEB J, Carcinogenesis, Mol Cancer Res, etc. His research work on gastric cancer has received State First Class Award for Science and Technology in China.
Dr. Xin-Yuan Guan got his PhD degree in 1993 at the University of Arizona. He was recruited by the National Human Genome Research Institute in NIH as a senior staff fellow. In 1999, Prof. Guan joined the Department of Clinical Oncology, The University of Hong Kong as an Associated Professor. He was promoted as Professor in 2007 and Chair Professor in 2018. He is now the Sophie YM Chan Professor in Cancer Research, Deputy Director of State Key Laboratory for Liver Research, and Director of Laboratory of Cancer Genetics, Li Ka Shing Faculty of Medicine, the University of Hong Kong. Prof. Guan's research interests include the identification and characterization of cancer-related genes, cancer stem cells and cancer microenvironment in hepatocellular, esophageal and nasopharyngeal carcinomas. Prof. Guan has published more than 320 peer-reviewed papers in international journals including in Nature Genetics, Cell Stem Cell, Nature Medicine, which have been cited for more than 23,800 times. He got many awards including National Outstanding Young Research Award (Type B, 1998), Outstanding Research Award of The University of Hong Kong (2012), Outstanding Research Student Supervisor Award of The University of Hong Kong (2016). State Natural Sciences Award of China (Second-class, 2010) and State Scientific and Technological Progress Award of China (First-class, 2012).
Congratulations on their achievements! We believe we will build the journal a bright future with the strong support of all our Editorial Board members and Junior Editorial members!